title: The Janus face of adenosine: antiarrhythmic and proarrhythmic actions.
abstract: Adenosine is a ubiquitous, endogenous purine involved in a variety of physiological and pathophysiological regulatory mechanisms. Adenosine has been proposed as an endogenous antiarrhythmic substance to prevent hypoxia/ischemia-induced arrhythmias. Adenosine (and its precursor, ATP) has been used in the therapy of various cardiac arrhythmias over the past six decades. Its primary indication is treatment of paroxysmal supraventricular tachycardia, but it can be effective in other forms of supraventricular and ventricular arrhythmias, like sinus node reentry based tachycardia, triggered atrial tachycardia, atrioventricular nodal reentry tachycardia, or ventricular tachycardia based on a cAMP-mediated triggered activity. The main advantage is the rapid onset and the short half life (1- 10 sec). Adenosine exerts its antiarrhythmic actions by activation of A1 adenosine receptors located in the sinoatrial and atrioventricular nodes, as well as in activated ventricular myocardium. However, adenosine can also elicit A2A, A2B and A3 adenosine receptor-mediated global side reactions (flushing, dyspnea, chest discomfort), but it may display also proarrhythmic actions mediated by primarily A1 adenosine receptors (e.g. bradyarrhythmia or atrial fibrillation). To avoid the non-specific global adverse reactions, A1 adenosine receptor- selective full agonists (tecadenoson, selodenoson, trabodenoson) have been developed, which agents are currently under clinical trial. During long-term administration with orthosteric agonists, adenosine receptors can be internalized and desensitized. To avoid desensitization, proarrhythmic actions, or global adverse reactions, partial A1 adenosine receptor agonists, like CVT-2759, were developed. In addition, the pharmacologically "silent" site- and event specific adenosinergic drugs, such as adenosine regulating agents and allosteric modulators, might provide attractive opportunity to increase the effectiveness of beneficial actions of adenosine and avoid the adverse reactions.
authors.forename: A József
authors.initials: AJ
authors.lastname: Szentmiklosi
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Galajda
authors.forename: Ágnes
authors.initials: Á
authors.lastname: Cseppento
authors.forename: Rudolf
authors.initials: R
authors.lastname: Gesztelyi
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Susán
authors.forename: Bence
authors.initials: B
authors.lastname: Hegyi
authors.affiliation: Department of Pharmacology and Pharmacotherapy, University of Debrecen, P.O. Box 12, H-4012 Debrecen, Nagyerdei krt. 98. Hungary. ajszm948@gmail.com.
authors.forename: Péter P
authors.initials: PP
authors.lastname: Nánási
mesh_terms: D000241:Adenosine / Q000494:pharmacology* / Q000502:physiology; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D002319:Cardiovascular System / Q000503:physiopathology; D006329:Heart Conduction System / Q000187:drug effects / Q000502:physiology; D006801:Humans; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000502:physiology
chemical_list: D000889:Anti-Arrhythmia Agents; D018047:Receptors, Purinergic P1; D000241:Adenosine